Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer
Purpose: The purpose of this retrospective study was to determine the association and prognostic value of body mass index (BMI) at the time of initial diagnosis in patients with locally advanced breast cancer (LABC). The analysis includes the subsets of inflammatory (IBC) and noninflammatory (non-IB...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2008-03, Vol.14 (6), p.1718-1725 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1725 |
|---|---|
| container_issue | 6 |
| container_start_page | 1718 |
| container_title | Clinical cancer research |
| container_volume | 14 |
| creator | DAWOOD, Shaheenah BROGLIO, Kristine GONZALEZ-ANGULO, Ana M KAU, Shu-Wan ISLAM, Rabiul HORTOBAGYI, Gabriel N CRISTOFANILLI, Massimo |
| description | Purpose: The purpose of this retrospective study was to determine the association and prognostic value of body mass index (BMI) at
the time of initial diagnosis in patients with locally advanced breast cancer (LABC). The analysis includes the subsets of
inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer.
Experimental Design: We identified 602 patients who had LABC treated on prospective clinical trials. BMI was divided into three groups: ( a ) ≤24.9 (normal/underweight), ( b ) 25.0 to 29.9 (overweight), and ( c ) ≥30 (obese). Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards were used
to determine associations between survival and BMI and to test for an interaction between BMI and breast cancer type.
Results: Eighty-two percent had non-IBC LABC and 18% had IBC. Obese patients tended to have a higher incidence of IBC compared with
overweight and normal/underweight groups ( P = 0.01). Median follow up was 6 years for all patients. Median overall survival (OS) and recurrence-free survival (RFS) were
8.8 and 5.9 years, respectively. Patients with LABC who were obese or overweight had a significantly worse OS and RFS ( P = 0.001) and a higher incidence of visceral recurrence compared with normal/underweight patients. In a multivariable model,
BMI remained significantly associated with both OS and RFS for the entire cohort. The interactions between BMI and LABC subsets
and between BMI and menopausal status were not statistically significant.
Conclusion: Patients with LABC and high BMI have a worse prognosis. Evaluation of the biological factors associated with this observation
can provide tools for additional therapeutic interventions. |
| doi_str_mv | 10.1158/1078-0432.CCR-07-1479 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70411495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70411495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-de9db3ef70570d19e53027694c34df75df4241a3967b0ba067ce1247f3ab99263</originalsourceid><addsrcrecordid>eNpFkE1P3DAQhq0KxFf5Ca18AXEJzMR2vD5CRFukRVRV26vl2BM2VTYBe7dl_z1Od1tOMyM9M6P3YewDwiWiml0h6FkBUpSXdf2tAF2g1OYdO0KldCHKSu3l_h9zyI5T-gWAEkEesEOcCalRl0fs9mscH4cxrTrPf7p-TXxs-c0YNvzepcTvhkAvvBv4fPSu7zf8Ovx2g6fAbyK5tOL1NMX3bL91faLTXT1hPz7dfq-_FPOHz3f19bzwUlSrIpAJjaBWg9IQ0JASUOrKSC9kaLUKrSwlOmEq3UDjoNKesJS6Fa4xpqzECTvf3n2K4_Oa0souu-Sp791A4zpZDRJRGpVBtQV9HFOK1Nqn2C1d3FgEO_mzkxs7ubHZnwVtJ3957-PuwbpZUnjb2gnLwNkOcCkbaWPO36X_XAk5gAGduYstt-geF3-6SNb_NRUpkYt-kd_ZyqLOh18BA1uEmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70411495</pqid></control><display><type>article</type><title>Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>DAWOOD, Shaheenah ; BROGLIO, Kristine ; GONZALEZ-ANGULO, Ana M ; KAU, Shu-Wan ; ISLAM, Rabiul ; HORTOBAGYI, Gabriel N ; CRISTOFANILLI, Massimo</creator><creatorcontrib>DAWOOD, Shaheenah ; BROGLIO, Kristine ; GONZALEZ-ANGULO, Ana M ; KAU, Shu-Wan ; ISLAM, Rabiul ; HORTOBAGYI, Gabriel N ; CRISTOFANILLI, Massimo</creatorcontrib><description>Purpose: The purpose of this retrospective study was to determine the association and prognostic value of body mass index (BMI) at
the time of initial diagnosis in patients with locally advanced breast cancer (LABC). The analysis includes the subsets of
inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer.
Experimental Design: We identified 602 patients who had LABC treated on prospective clinical trials. BMI was divided into three groups: ( a ) ≤24.9 (normal/underweight), ( b ) 25.0 to 29.9 (overweight), and ( c ) ≥30 (obese). Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards were used
to determine associations between survival and BMI and to test for an interaction between BMI and breast cancer type.
Results: Eighty-two percent had non-IBC LABC and 18% had IBC. Obese patients tended to have a higher incidence of IBC compared with
overweight and normal/underweight groups ( P = 0.01). Median follow up was 6 years for all patients. Median overall survival (OS) and recurrence-free survival (RFS) were
8.8 and 5.9 years, respectively. Patients with LABC who were obese or overweight had a significantly worse OS and RFS ( P = 0.001) and a higher incidence of visceral recurrence compared with normal/underweight patients. In a multivariable model,
BMI remained significantly associated with both OS and RFS for the entire cohort. The interactions between BMI and LABC subsets
and between BMI and menopausal status were not statistically significant.
Conclusion: Patients with LABC and high BMI have a worse prognosis. Evaluation of the biological factors associated with this observation
can provide tools for additional therapeutic interventions.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-07-1479</identifier><identifier>PMID: 18347172</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Body Mass Index ; Breast cancer ; Breast Neoplasms - complications ; Breast Neoplasms - diagnosis ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Disease Progression ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; Inflammatory breast cancer ; Intestinal Neoplasms - secondary ; Locally advanced breast Cancer ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Obesity - complications ; Pharmacology. Drug treatments ; Prognosis ; Recurrence ; Survival Analysis ; Tumors</subject><ispartof>Clinical cancer research, 2008-03, Vol.14 (6), p.1718-1725</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-de9db3ef70570d19e53027694c34df75df4241a3967b0ba067ce1247f3ab99263</citedby><cites>FETCH-LOGICAL-c436t-de9db3ef70570d19e53027694c34df75df4241a3967b0ba067ce1247f3ab99263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20241907$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18347172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAWOOD, Shaheenah</creatorcontrib><creatorcontrib>BROGLIO, Kristine</creatorcontrib><creatorcontrib>GONZALEZ-ANGULO, Ana M</creatorcontrib><creatorcontrib>KAU, Shu-Wan</creatorcontrib><creatorcontrib>ISLAM, Rabiul</creatorcontrib><creatorcontrib>HORTOBAGYI, Gabriel N</creatorcontrib><creatorcontrib>CRISTOFANILLI, Massimo</creatorcontrib><title>Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: The purpose of this retrospective study was to determine the association and prognostic value of body mass index (BMI) at
the time of initial diagnosis in patients with locally advanced breast cancer (LABC). The analysis includes the subsets of
inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer.
Experimental Design: We identified 602 patients who had LABC treated on prospective clinical trials. BMI was divided into three groups: ( a ) ≤24.9 (normal/underweight), ( b ) 25.0 to 29.9 (overweight), and ( c ) ≥30 (obese). Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards were used
to determine associations between survival and BMI and to test for an interaction between BMI and breast cancer type.
Results: Eighty-two percent had non-IBC LABC and 18% had IBC. Obese patients tended to have a higher incidence of IBC compared with
overweight and normal/underweight groups ( P = 0.01). Median follow up was 6 years for all patients. Median overall survival (OS) and recurrence-free survival (RFS) were
8.8 and 5.9 years, respectively. Patients with LABC who were obese or overweight had a significantly worse OS and RFS ( P = 0.001) and a higher incidence of visceral recurrence compared with normal/underweight patients. In a multivariable model,
BMI remained significantly associated with both OS and RFS for the entire cohort. The interactions between BMI and LABC subsets
and between BMI and menopausal status were not statistically significant.
Conclusion: Patients with LABC and high BMI have a worse prognosis. Evaluation of the biological factors associated with this observation
can provide tools for additional therapeutic interventions.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Body Mass Index</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Inflammatory breast cancer</subject><subject>Intestinal Neoplasms - secondary</subject><subject>Locally advanced breast Cancer</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Obesity - complications</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1P3DAQhq0KxFf5Ca18AXEJzMR2vD5CRFukRVRV26vl2BM2VTYBe7dl_z1Od1tOMyM9M6P3YewDwiWiml0h6FkBUpSXdf2tAF2g1OYdO0KldCHKSu3l_h9zyI5T-gWAEkEesEOcCalRl0fs9mscH4cxrTrPf7p-TXxs-c0YNvzepcTvhkAvvBv4fPSu7zf8Ovx2g6fAbyK5tOL1NMX3bL91faLTXT1hPz7dfq-_FPOHz3f19bzwUlSrIpAJjaBWg9IQ0JASUOrKSC9kaLUKrSwlOmEq3UDjoNKesJS6Fa4xpqzECTvf3n2K4_Oa0souu-Sp791A4zpZDRJRGpVBtQV9HFOK1Nqn2C1d3FgEO_mzkxs7ubHZnwVtJ3957-PuwbpZUnjb2gnLwNkOcCkbaWPO36X_XAk5gAGduYstt-geF3-6SNb_NRUpkYt-kd_ZyqLOh18BA1uEmw</recordid><startdate>20080315</startdate><enddate>20080315</enddate><creator>DAWOOD, Shaheenah</creator><creator>BROGLIO, Kristine</creator><creator>GONZALEZ-ANGULO, Ana M</creator><creator>KAU, Shu-Wan</creator><creator>ISLAM, Rabiul</creator><creator>HORTOBAGYI, Gabriel N</creator><creator>CRISTOFANILLI, Massimo</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080315</creationdate><title>Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer</title><author>DAWOOD, Shaheenah ; BROGLIO, Kristine ; GONZALEZ-ANGULO, Ana M ; KAU, Shu-Wan ; ISLAM, Rabiul ; HORTOBAGYI, Gabriel N ; CRISTOFANILLI, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-de9db3ef70570d19e53027694c34df75df4241a3967b0ba067ce1247f3ab99263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Body Mass Index</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Inflammatory breast cancer</topic><topic>Intestinal Neoplasms - secondary</topic><topic>Locally advanced breast Cancer</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Obesity - complications</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAWOOD, Shaheenah</creatorcontrib><creatorcontrib>BROGLIO, Kristine</creatorcontrib><creatorcontrib>GONZALEZ-ANGULO, Ana M</creatorcontrib><creatorcontrib>KAU, Shu-Wan</creatorcontrib><creatorcontrib>ISLAM, Rabiul</creatorcontrib><creatorcontrib>HORTOBAGYI, Gabriel N</creatorcontrib><creatorcontrib>CRISTOFANILLI, Massimo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAWOOD, Shaheenah</au><au>BROGLIO, Kristine</au><au>GONZALEZ-ANGULO, Ana M</au><au>KAU, Shu-Wan</au><au>ISLAM, Rabiul</au><au>HORTOBAGYI, Gabriel N</au><au>CRISTOFANILLI, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2008-03-15</date><risdate>2008</risdate><volume>14</volume><issue>6</issue><spage>1718</spage><epage>1725</epage><pages>1718-1725</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: The purpose of this retrospective study was to determine the association and prognostic value of body mass index (BMI) at
the time of initial diagnosis in patients with locally advanced breast cancer (LABC). The analysis includes the subsets of
inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer.
Experimental Design: We identified 602 patients who had LABC treated on prospective clinical trials. BMI was divided into three groups: ( a ) ≤24.9 (normal/underweight), ( b ) 25.0 to 29.9 (overweight), and ( c ) ≥30 (obese). Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards were used
to determine associations between survival and BMI and to test for an interaction between BMI and breast cancer type.
Results: Eighty-two percent had non-IBC LABC and 18% had IBC. Obese patients tended to have a higher incidence of IBC compared with
overweight and normal/underweight groups ( P = 0.01). Median follow up was 6 years for all patients. Median overall survival (OS) and recurrence-free survival (RFS) were
8.8 and 5.9 years, respectively. Patients with LABC who were obese or overweight had a significantly worse OS and RFS ( P = 0.001) and a higher incidence of visceral recurrence compared with normal/underweight patients. In a multivariable model,
BMI remained significantly associated with both OS and RFS for the entire cohort. The interactions between BMI and LABC subsets
and between BMI and menopausal status were not statistically significant.
Conclusion: Patients with LABC and high BMI have a worse prognosis. Evaluation of the biological factors associated with this observation
can provide tools for additional therapeutic interventions.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>18347172</pmid><doi>10.1158/1078-0432.CCR-07-1479</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2008-03, Vol.14 (6), p.1718-1725 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70411495 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Body Mass Index Breast cancer Breast Neoplasms - complications Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - pathology Disease Progression Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Inflammatory breast cancer Intestinal Neoplasms - secondary Locally advanced breast Cancer Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Obesity - complications Pharmacology. Drug treatments Prognosis Recurrence Survival Analysis Tumors |
| title | Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A56%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Value%20of%20Body%20Mass%20Index%20in%20Locally%20Advanced%20Breast%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=DAWOOD,%20Shaheenah&rft.date=2008-03-15&rft.volume=14&rft.issue=6&rft.spage=1718&rft.epage=1725&rft.pages=1718-1725&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-07-1479&rft_dat=%3Cproquest_cross%3E70411495%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70411495&rft_id=info:pmid/18347172&rfr_iscdi=true |